That is very important, because the way a protein in the human body folds identifies if a pharmaceutical will have the ability to bind to that protein and work. To put it simply, we need to understand how these proteins fold if we desire a drug to work. Historically, this has been an experimental procedure (jeff brown biotech stocks). And now, Alpha, Fold can predict protein folding with 92. 4% accuracy. That's going to make it a lot easier to create drugs that do what they're developed to do. This was an advancement nearly no one discovered. However it's going to have extensive ramifications for treating illness. I forecast that Alpha, Fold will be 98% accurate by the end of 2021.
And, naturally, there will be plenty of investment chances in this area, too. Shifting topics It's going to be an excellent year for bitcoin. I'm bullish on it in 2021 (exponential tech investor). That said, I still think bitcoin will continue to be volatile. We're close to all-time highs. I would not be surprised if it pulled back maybe considerably before going greater - jeff brown prediction for 2021. I have actually been covering bitcoin for a long period of time now. Among the very first research reports I ever released was on bitcoin. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
However at the time of that preliminary suggestion, I titled my report "What's the Big Deal With Bitcoin?" That shows you where the discussion was at the time. We were primarily informing readers. But that's not the huge concern anymore. Now we're seeing institutional money lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, niche business. Mass, Mutual is a relied on 170-year-old institution. So think of that. In 5 years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
Which's a huge reason I'm bullish on it this year. jeff brown genetic sequencer stock. Regards, Jeff Brown, Editor, The Bleeding Edge I have a perk prediction 2020 was a record year for IPOs. 552 U.S. business went public the most in more than twenty years. These companies raised a total of $172 billion. That's an all-time high beating the previous yearly record by 43%. I forecast 2021 will be another record year in IPOs. There are many fantastic personal business on the edge of striking the general public markets And I've been working on a brand-new method for you to invest even before these companies go public.
This opportunity has actually been building over the last couple of years. I can't wait to tell you all about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Occasion to find out all the details. Go right here to reserve your area free of charge.
Emma Walsh here, managing editor of the Journal. Routine Journal readers know that tech isn't our normal beat (korean actress). And when it pertains to tech investing, we leave it to the specialists. Thankfully, we have several such specialists in our Rolodex. Our associate Jeff Brown will recognize to our long time readers. He is one of the most accomplished tech investing experts we understand (jeff brown biotech genome sequencing). In fact, he had several triple-digit returns in his Brownstone Research study portfolios last year. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to have a look at the big photo and anticipate what's simply around the corner.
That consists of things like 5G networks, biotech, expert system, and far more. These trends are experiencing exponential growth and producing amazing chances for financiers. I wish to ensure all our readers are prepared for what's next. And with that in mind, let me draw the photo of what I see coming in the next 12 months Our new 5G (fifth-generation) wireless networks are a subject I have actually been covering for years now. jeff brown investor prediction. However regardless of what many readers might believe, this is a trend that's simply beginning. Even though the COVID-19 pandemic disrupted supply chains last year, an outstanding 250 million 5G-enabled gadgets were still sold.
And all of this eventually resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by two months (toxic tech 5 tech darlings). Losing two months of production and sales actually affects the number of 5G gadgets are sold in the fiscal year. When you think about all of that, selling 250 million units is amazing. More significantly, the hold-ups triggered by the pandemic created a lots of pent-up demand. And that need is now going to be pressed into 2021. In truth, I anticipate that more than 500 million 5G gadgets will be delivered in 2021 - jeff brown stock market prediction. Which's not my only 5G forecast When I have actually discussed 5G in the past, I've explained its 3 different phases.
In Stage 2, 5G gadgets go on sale. 5G phones and other items start to reach customers. And in Stage Three, 5G services start to be offered (biotech stocks). That's when we start to see applications running on 5G networks. Think about things like enormous multiplayer games over a smart phone. That's not possible with 4G. It will be with 5G. And my second 5G forecast for 2021 is that we will start Phase Three by this summer season. This starts something of a virtuous cycle: Most people don't truly care about the innovation. But they will care if there are interesting applications that can only be accessed with a 5G phone.
That causes more 5G apps being established. In fact, 5G is going to open up a suite of incredible applications: self-driving automobiles, the Internet of Things, robotic surgery, and more. All of these technologies need 5G. The financial investment chances going forward will be huge. Stepping far from 5G, the next crucial technology I predict in 2021 is CRISPR hereditary editing. CRISPR stands for "clustered regularly interspaced brief palindromic repeat." It's a mouthful. But it's one of the most amazing developments in biotechnology. At a high level, CRISPR is a technology that can modify our hereditary makeup as if it were software.
The program can crash or not operate properly. CRISPR uses a comparable concept but with our genetic code. "Typos" in our genome can lead to illness. CRISPR can remedy these "typos." For years, CRISPR was mainly a specific niche technology that wasn't well comprehended. And throughout that time, there were truly just 3 companies running in this area. But things are altering. CRISPR is no longer simply theoretical. We're seeing real results. We're dealing with diseases and seeing that this innovation simply works. And as an outcome, a "2nd crop" of early-stage CRISPR companies is going public and providing unbelievable returns. This entire market is successfully a greenfield chance.
There's space for lots of business to exist in this area. tech predictions. And there will be more. That's my prediction for CRISPR in 2021. I predict that two or three more hereditary editing companies will hold their IPOs. Sticking with biotechnology, we are seeing remarkable things taking place at the convergence of biotech and synthetic intelligence (AI). Google's AI subsidiary, Deep, Mind, just announced at the end of 2020 that its newest Alpha, Fold software can accurately forecast the folding of a protein based exclusively on its amino acid series with 92. 4% accuracy. That is very important due to the fact that the way a protein in the human body folds identifies if a pharmaceutical will be able to bind to that protein and work.
Historically, this has actually been an experimental procedure. Today, Alpha, Fold can forecast protein folding with 92. 4% accuracy. That's going to make it much simpler to develop drugs that do what they're created to do. And here's my next forecast. I anticipate that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not just one but several drug therapies produced utilizing this technology. This was one of those advancements that almost no one observed. But it's going to have profound ramifications for treating disease. And, of course, there will be plenty of investment chances in this area, too.
It's going to be a great year for bitcoin. I'm bullish on it in 2021. That stated, I still think bitcoin will continue to be unpredictable. We're close to all-time highs. I wouldn't be shocked if it drew back perhaps significantly before going higher. I've been covering bitcoin for a very long time now. One of the first research reports I ever released was on bitcoin - white house. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on investment for any person who followed my recommendation. However at the time of that preliminary recommendation, I entitled my report, "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time.
But no one is asking that concern any longer. Now, we're seeing institutional cash lastly taking an interest in bitcoin. The big news was that Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, niche business. tech stocks. Mass, Mutual is a 150-year-old organization. So consider that. In five years, we went from educating readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a huge factor why I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more perk prediction In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown deserves about $27. 5 million and claims the info depends on date since February 2021, however we could not independently verify this claim. Provided Jeff Brown's past, he likely has a considerable net worth, however we can't hammer down a precise figure at this minute. Brown is best known for his sage-like capability to select winning technology stocks. He spent more than 25 years looking into technology business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's comprehensive experience offers him an excellent perspective on the marketplace. He's constantly on the hunt for brand-new opportunities, and he shares many of his best choices in the Future Report.
That's high appreciation, however it's not ridiculously reasoned. Brown has an outstanding reputation as a stock-picker, and he effectively anticipated some of the most significant economic events of the past 20 years. Although he does not appear to launch his choices to the general public, the service's success is a direct indicator of Brown's stock-picking prowess. Nobody on Wall Street gets it ideal whenever, however Jeff Brown's precise forecasts have actually earned him legions of devoted followers. That says a lot about his ability. The Future Report is published by Brownstone Research, a prominent financial research publisher. Brownstone Research study provides a number of research study services with a wide array of specializations - social media.
The business is likewise affiliated with Bonner & Partners, another well-respected research publisher - jeff brown genome sequencing stock. On its site, Brownstone says its mission is to provide retail investors with professional-grade research study: "For too long, the very best financial investment research has not been offered to private financiers. It has been usually booked for investment banks, hedge funds, private equity, and high-net-worth clients. jeff brown biotech stock. The mission of Brownstone Research study is to make that sort of exclusive research readily available to any investors looking to get an edge in the marketplaces. The objective is simple to deliver distinct and profitable investment research found nowhere else." -Brownstone Research study site excerpt from the Jeff Brown is the creator of Brownstone Research, and he also works as the firm's Chief Financial investment Expert.
With Brown guiding the ship, Brownstone Research study is a powerhouse publisher with lots to provide its customers. After years of steady success at the helm of top-tier companies like Tesla and Area, X, Elon Musk is a family name throughout the majority of America. If you know even a bit about the marketplace, you know that he has a track record as a King Midas of sorts. tech stocks. Everything he touches relies on gold! Jeff is well aware of Elon Musk's executive prowess, so he always has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next huge task.
In reality, Brown thinks S.A.V. jeff brown biotech genome sequencing. could be "the greatest trend of the 2020s, and he's not alone. Take a look at these quotes from other popular S.A.V. bulls: Elon's next huge act will be marrying 2 cutting-edge technologies: synthetic intelligence and electric cars and trucks. Musk hopes the mix will assist him develop the first fully-autonomous, self-driving cars and trucks ever. It's absolutely nothing brief of the automotive market's Holy Grail. As you know, electrical automobiles and self-driving automobile stocks have actually been big this year, but the Wall Street machine has been huge on buzz without much tangible outcome. In spite of a drastic boost in competition over the past few years, Brown still thinks Musk has the very best chance of putting everything together.
tech could be the magic string that ties all of it together. S.A.V. represents Shared Autonomous Car, and it might be the future of transport. Basically, this innovation would permit you to lease out your vehicle as a self-governing, self-driving taxi when you're not utilizing it. You just get out of the automobile and press a button on an app that informs the vehicle to "sign up with the fleet." Next thing you understand, you're unwinding on your couch while your automobile shuttles ride-sharers around town. Most importantly, you get to keep a significant chunk of the earnings. It sounds outrageous, but it could be closed than you believe.